Enteris BioPharma's Formulation Technology Enables Oral Delivery of Cara Therapeutics' CR845 Peptide for Acute and Chronic Pain in Phase 1a / 1b Trial
PR Newswire - Tue Dec 09, 7:10AM CST
Enteris BioPharma, Inc., an industry leader in oral peptide delivery, congratulates Cara Therapeutics (Nasdaq: CARA) on the successful completion of the Phase 1a / 1b clinical trial of its peripherally-selective kappa opioid agonist, CR845, for the treatment of acute and chronic pain. Cara's tablet formulation of CR845 utilizes Enteris' proprietary oral delivery technology.
CARA: 9.94 (-0.06)
Novus Becomes an Insurance Leader as MMJ Market Approaches Tipping Point
ACCESSWIRE - Mon Dec 08, 9:21AM CST
WHITEFISH, MT / ACCESSWIRE / December 8, 2014 / A unique company in the MMJ space today that is focused on the medical insurance side of the business is Novus Acquisition & Development (OTC: NDEV). Novus provides health insurance and insurance related solutions to the growing wellness and MMJ markets using an innovative cost-saving provider network model that is administered via their wholly-owned Novus Medical Group subsidiary's Novus MedPlan. The timely rollout of the Novus MedPlan in states where MMJ is legal, which gives patients access to considerable discounts on MMJ products for a modest subscriber fee of under $20 a month, was recently highlighted in Forbes as the number one pick, taking the top slot out of a list of the eight hottest publicly traded companies to draw the interest of investors in this rapidly emerging sector.
CARA: 9.94 (-0.06), INSY: 41.00 (+1.82), GWPH: 72.41 (+1.18)
Cara Therapeutics (CARA) in Focus: Stock Rises 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 8:46AM CST
Cara Therapeutics (CARA) was a big mover last session, with shares rising just over 6% on the day.
BIIB: 344.49 (+2.16), CARA: 9.94 (-0.06), ANIP: 54.28 (+2.33), AFFX: 8.94 (-0.36)
New Medical Chief at Cara
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 9:29AM CST
CARA: 9.94 (-0.06)
Cara Therapeutics Announces Appointment of Joseph Stauffer, D.O., as Chief Medical Officer
GlobeNewswire - Tue Dec 02, 7:05AM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the appointment of Joseph Stauffer, D.O., as Chief Medical Officer, effective immediately. Dr. Stauffer will oversee the clinical development of Cara's lead compound, CR845, as well as its pipeline of other novel pain therapies.
CARA: 9.94 (-0.06)
Cara Therapeutics Announces Positive Top-Line Results From Phase 1a / 1b Trial of Tablet Formulation of Oral CR845 for the Treatment of Acute and Chronic Pain
GlobeNewswire - Tue Dec 02, 7:00AM CST
-- All tested tablet strengths pharmacologically active, safe and well tolerated after single and multiple dose administration
CARA: 9.94 (-0.06)
Cara Therapeutics to Webcast Presentation at 26th Annual Piper Jaffray Healthcare Conference
GlobeNewswire - Tue Nov 25, 3:01PM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 26 Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014, at 2:30 p.m. ET in New York City.
CARA: 9.94 (-0.06)
Cara Therapeutics to Webcast Presentation at 2014 Stifel Healthcare Conference
GlobeNewswire - Tue Nov 11, 3:01PM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will present a company overview at the 2014 Stifel Healthcare Conference on Tuesday, November 18, 2014, at 2:25 p.m. ET in New York City.
CARA: 9.94 (-0.06)
Cara Therapeutics ups revenues 10% in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:59AM CST
CARA: 9.94 (-0.06)
Cara Therapeutics' (CARA) CEO Derek Chalmers on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 7:44PM CST
CARA: 9.94 (-0.06)
Cara Therapeutics misses by $0.07
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:18PM CST
CARA: 9.94 (-0.06)
Cara Therapeutics Reports Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 10, 3:11PM CST
-- Reported positive top-line data from human abuse liability trial for I.V. CR845
CARA: 9.94 (-0.06)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:35PM CST
HK: 2.01 (-0.09), WWD: 48.04 (-1.66), LLNW: 2.86 (+0.01), FXEN: 1.60 (-0.07), RMTI: 8.20 (+0.04), CZR: 12.83 (-2.03), EGY: 4.49 (-0.06), ICUI: 80.95 (-1.04), ICEL: 5.19 (-0.28), SAAS: 8.09 (-0.14), DMD: 6.35 (+0.09), NPSP: 31.28 (-0.99), SCLN: 8.23 (-0.32), ATHX: 1.36 (+0.05), CMLS: 3.87 (+0.03), TC: 1.38 (-0.07), ATW: 27.19 (-0.52), CLUB: 6.22 (+0.01), RAX: 45.39 (-0.86), PTLA: 28.27 (-0.27), IPAR: 26.05 (-0.73), ATLS: 26.31 (-0.13), AMBC: 23.08 (-0.97), CUI: 7.37 (-0.12), PDLI: 7.41 (-0.08), OMER: 22.81 (+0.12), PRAA: 57.23 (-0.17), CARA: 9.94 (-0.06), HALO: 7.99 (-0.16), MODN: 10.50 (+0.05), CALL: 7.70 (-0.05), ASEI: 47.24 (-1.33), HGR: 21.22 (+0.21), ERII: 4.72 (+0.06)
Cara Therapeutics reports November 10
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 3:22PM CST
CARA: 9.94 (-0.06)
Cara Therapeutics to Announce Third Quarter 2014 Financial Results on November 10, 2014
GlobeNewswire - Mon Nov 03, 3:01PM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that the Company will host a conference call and live audio webcast on Monday, November 10, 2014, at 4:30 p.m. ET to report third quarter 2014 financial results and provide a corporate update.
CARA: 9.94 (-0.06)
Cara Therapeutics (CARA) Worth Watching: Stock Rises 6.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:39AM CDT
Cara Therapeutics Inc. (CARA) was a big mover last session, as its shares rose over 6% on the day.
MDVN: 106.86 (-1.16), MACK: 10.64 (+0.42), CARA: 9.94 (-0.06), ILMN: 184.30 (-2.53)
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 8:15AM CDT
CAMT: 3.03 (-0.05), ORB: 22.75 (-1.09), UNIS: 2.86 (-0.10), ALLY: 22.19 (-0.45), FB: 77.83 (+0.10), AMCC: 5.87 (+0.03), INVN: 15.18 (-0.29), AKS: 5.20 (-0.13), NBG: 1.79 (-0.01), RFMD: 15.50 (-0.29), BLDP: 1.86 (-0.03), CARA: 9.94 (-0.06), GT: 26.49 (-0.60), HIVE: 4.54 (-0.15), MCGC: 3.66 (+0.08), IBIO: 0.69 (unch), BIOS: 5.91 (-0.12), UBA: 22.08 (-0.31), ARCP: 8.99 (-0.24), SNY: 45.16 (-1.05), STM: 7.34 (-0.15), X: 27.82 (-0.72)
Cara Therapeutics' pain drug positive in human abuse liability trial
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 7:42AM CDT
CARA: 9.94 (-0.06)
Cara Therapeutics Announces Positive Results From Human Abuse Liability Trial of Peripheral Opioid for Acute Pain, I.V. CR845
GlobeNewswire - Wed Oct 29, 6:00AM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain without eliciting typical opioid (narcotic) side effects, today announced positive results from its Human Abuse Liability (HAL) trial of an intravenous (I.V.) formulation of CR845, a first-in-class peripherally-selective kappa opioid agonist.
CARA: 9.94 (-0.06)
4 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Oct 29, 6:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
CARA: 9.94 (-0.06), LIOX: 5.50 (-0.07), QRHC: 1.29 (-0.02), TWI: 9.76 (-0.17)